Mission Statment
InnaVirVax is a privately-owned biopharmaceutical company dedicated to the development of a cutting edge discovery in the field of therapy/prevention and prognostic of AIDS and HIV infection and new cancer therapies.

Company Mission
InnaVirVax is developing product candidates resulting from a beakthrough discovery. Based on a new paradigm (i.e. the understanding of the mechanism responsible for the decline of the CD4+ T lymphocytes in HIV-infected patients), the products currently developed by InnaVirVax will allow the prevention and the treatment of AIDS in HIV-infected patients. Moreover InnaVirVax has an AIDS prognostic test in its R&D portfolio.  
Lastly, InnaVirVax is developing an innovative cancer biotherapy relying on a totally new tumor surface antigen.
InnaVirVax product portfolio originates from Inserm, the French Medical research council, the AP-HP, the largest hospital in Europe, and University Pierre et Marie Curie in Paris.

Proprietary technology  

The discovery made by the founders of InnaVirVax has identified that a dysregulation of the innate immune system is responsible for the loss of CD4+ T lymphocytes in HIV-infected patients. The understanding of this dysregulation (resulting in the presence at the surface of the CD4+ T  lymphocytes of a NK cell ligand, making CD4+ T lymphoyctes sensitive to NK-mediated cell lysis) has allowed InnaVirVax and its academic partners to design a therapeutic vaccine for HIV infection that has been successfully tested in non human primates The knowledge of the above described mechanism has also enabled InnaVirVax to develop a prognostic test for the onset of AIDS in asymptomatic HIV-infected patients.
In addition InnaVirVax is developing an innovative cancer therapy based on a new tumor cell surface antigen.

 

Intellectual Property
The products developed by InnaVirVax are covered by two patent families among which are WO 2004/070385 and WO 2005/076001. 

Alliances
InnaVirVax is seeking for industrial alliances with corporate partners able to further develop and commercialize InnaVirVax product candidates.